

CD57 siRNA (h): sc-42798

BACKGROUND

Over 100 cell surface markers have been identified through the use of monoclonal antibodies. Many of these markers have proven useful in identifying a specific subpopulation of cells within a mixed colony. Accordingly, these molecules have been assigned a "cluster of differentiation" (CD) designation. T lymphocytes displaying the natural killer (NK) cell marker CD57 (also designated Leu7) on their cell surface are distinguishable from other T cell subsets by their granular lymphocyte morphology and their clonal expansion in patients with AIDS and in recipients of bone marrow transplantation. CD57-positive cells have also been shown to localize to sites of certain tumors and large numbers of these cells are detected in the synovial fluid from patients suffering from rheumatoid arthritis.

REFERENCES

- Holter, W., et al. 1991. Phenotypical and functional characterization of leukocytes—the CD-system. *Wien. Klin. Wochenschr.* 103: 247-262.
- Dupuy d'Angeac, A., et al. 1993. Increased percentage of CD3⁺, CD57⁺ lymphocytes in patients with rheumatoid arthritis. *Arthritis Rheum.* 36: 608-612.
- Kamel, O.W., et al. 1993. Leu7 (CD57) reactivity distinguishes nodular lymphocyte predominance Hodgkin's disease from nodular sclerosing Hodgkin's disease, T-cell-rich B-cell lymphoma and follicular lymphoma. *Am. J. Pathol.* 142: 541-546.
- Yamashita, N., et al. 1993. Phenotypic properties and cytotoxic functions of human CD8⁺ cells expressing the CD57 antigen. *Nat. Immun.* 12: 79-91.
- Fukuda, H., et al. 1994. Marked increase of CD8⁺S6F1⁺ and CD8⁺CD57⁺ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation. *Bone Marrow Transplant.* 13: 181-185.
- Kim, Y.B., et al. 1994. CD11/CD18 panel report for swine CD workshop. *Vet. Immunol. Immunopathol.* 43: 289-291.
- Okada, T., et al. 1995. Origin of CD57⁺ T cells which increase at tumour sites in patients with colorectal cancer. *Clin. Exp. Immunol.* 102: 159-166.
- Kern, F., et al. 1996. The enigma of CD57⁺CD28⁺ T cell expansion—energy or activation? *Clin. Exp. Immunol.* 104: 180-184.

CHROMOSOMAL LOCATION

Genetic locus: B3GAT1 (human) mapping to 11q25.

PRODUCT

CD57 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see CD57 shRNA Plasmid (h): sc-42798-SH and CD57 shRNA (h) Lentiviral Particles: sc-42798-V as alternate gene silencing products.

For independent verification of CD57 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-42798A, sc-42798B and sc-42798C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

CD57 siRNA (h) is recommended for the inhibition of CD57 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

CD57 (NK-1): sc-6261 is recommended as a control antibody for monitoring of CD57 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor CD57 gene expression knockdown using RT-PCR Primer: CD57 (h)-PR: sc-42798-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.